ImmuneOnco Biopharmaceuticals
PublicImmuneOnco Biopharmaceuticals is now publicly traded
The data on this page reflects ImmuneOnco Biopharmaceuticals's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Sep 5, 2023
Last Round
Follow-on Offering
Oct 15, 2025
Total Funding Raised
$214.81M
Company Overview
ImmuneOnco (HKG: 01541) is a biotechnology company focused on developing innovative immuno-oncology therapies through a systematic approach that leverages both innate and adaptive immune systems.
Sector
Healthcare
AI Layer
Non-AI
Keywords
CD47-targeted immuno-oncologySIRPα-Fc fusion proteinbispecific antibody therapeuticsinnate and adaptive immunity therapiesCD47-SIRPα pathway modulationtherapies for hematological malignanciesbiopharmaceutical out-licensing modelCD47 therapies with improved safety profiletherapies for solid tumorsfusion protein therapeuticsADCC-enhanced CTLA-4 monoclonal antibodytherapies for autoimmune diseases
ImmuneOnco Biopharmaceuticals Comparables
Compare ImmuneOnco Biopharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Immune-Onc Therapeutics | 77% | |
| Curon Biopharmaceutical | 71% | |
| OPSYON Therapeutics | 68% | |
ImmuneOnco Biopharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Oct 15, 2025 | ||||
| IPO | Sep 5, 2023 | ||||
| Series C | Mar 24, 2021 | ||||
| Series B | Oct 23, 2020 | ||||
| Early Funding | Feb 1, 2020 | ||||
Early Funding | Feb 1, 2017 |
ImmuneOnco Biopharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| IDG Capital | Series A |
| Shanghai Zhangjiang Science & Technology Venture Capital | Seed |
| GBA Holdings | Series C |
| Zhonghai Investment | Series A |
| LYFE Capital | Series B, Series C |
| Shanghai International Group | Series C |
| Lilly Asia Ventures | Series B, Series C |
ImmuneOnco Biopharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Firmographic Details
HeadquartersShanghai, Shanghai
Employee Range15
Year Founded2015
Last FundingOct 15, 2025